Pesquisar
Black Diamond Therapeutics Inc
BDTXAdicionar à lista de desejos
2.010USD
+0.170+9.24%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
114.46MValor de mercado
PerdaP/L TTM
Mais detalhes de Black Diamond Therapeutics Inc Empresa
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Informações de Black Diamond Therapeutics Inc
Código da empresaBDTX
Nome da EmpresaBlack Diamond Therapeutics Inc
Data de listagemJan 30, 2020
CEOVelleca (Mark A)
Número de funcionários24
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 30
Endereço245 First Street, 18Th Floor
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Telefone16174175868
Sitehttps://www.blackdiamondtherapeutics.com/
Código da empresaBDTX
Data de listagemJan 30, 2020
CEOVelleca (Mark A)
Executivos da empresa Black Diamond Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Brent M. Hatzis-Schoch, Esq.
Mr. Brent M. Hatzis-Schoch, Esq.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Black Diamond Therapeutics Inc?
Os cinco principais acionistas de Black Diamond Therapeutics Inc são: Dr. Ali Behbahani, M.D.
Quantas instituições possuem ações da Black Diamond Therapeutics Inc (BDTX)?
Em 2026Q1, 265 instituições possuíam ações da Black Diamond Therapeutics Inc, com valor de mercado aproximado de 45.02M, representando 78.72% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -14972289.00.